|
|
50 South Buckhout Street, Suite 1
Irvington, NY 10533 USA
phone:914-591-3783
fax:914-591-3785
|
|
| Symbol |
MELA |
| Exchange |
NASDAQ |
| Founded |
1989 |
| Employees |
|
|
|
| www.eosciences.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma. |
|
| Management |
| Joseph V. Gulfo, MD, President & CEO, Director; Richard I. Steinhart, Vice President, Finance, and Chief Financial Officer and Treasurer; Tina Cheng-Avery, Vice President, Commercialization; Nick Kabelev, Vice President, R & D; Chris Butler, Vice President, Operations |
| |
|
|
|
|
|
|
|
| Keywords |
| premarket approval, melafind, food and drug administration, medical technology, skin lesions |
|
|
|
| Description |
|
Electro-Optical Sciences (EOS) develops non-invasive, point-of-care instruments to assist in the early diagnosis of melanoma. The company's flagship product is MelaFind, a tool for detecting melanoma. MelaFind has not yet received regulatory approval and generates no revenue. |
|
| Products / Services |
MelaFind is a hand-held imaging device that captures images of suspicious pigmented skin lesions and extracts data.
|
|
| Technology / Differentiation |
| MelaFind uses visible and infrared light to capture images of suspicious pigmented skin lesions, which are then analyzed against a proprietary database of melanomas and benign lesions. The database includes results of over 5,000 biopsied lesions from over 3,500 patients. The MelaFind system uses a Lesion Classifier to distinguish between melanoma from non-melanoma lesions, using EOS' lesion database and mathematical algorithms. |
|
| Market / Customers |
Melanoma is responsible for around 80% of skin cancer fatalities. There is currently no cure for advanced stage melanoma and treatment costs are estimated to run up to $170,000 per patient. However, early detection almost always leads to a cure with relatively minimal costs.
|
|
| Competitors / Substitutes / Alternatives |
Optiscan Imaging, Welch Allyn
|
|
| Status |
| The MelaFind system is currently under clinical investigation and is not yet available for commercial distribution in the United States or any other country. EOS does not expect to be able to commercialize MelaFind before 2007. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members